MedTrace Logo

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2026-05-22

No results posted yet for this study

Summary

This is an open-label, non-randomized, single-center, phase II study to evaluate the efficacy, toxicity and, tolerability of pre-specified dose attenuated chemotherapy regimens in lung cancer patients with comorbidities.

Conditions

  • Lung Cancer
  • Small-cell Lung Cancer
  • Non Small Cell Lung Cancer

Interventions

DRUG

Carboplatin

Standard of care chemotherapy regimen

DRUG

Pemetrexed

Standard of care chemotherapy regimen

DRUG

Paclitaxel

Standard of care chemotherapy regimen

DRUG

Nab paclitaxel

Standard of care chemotherapy regimen

DRUG

Docetaxel

Standard of care chemotherapy regimen

DRUG

Gemcitabine

Standard of care chemotherapy regimen

DRUG

Etoposide

Standard of care chemotherapy regimen

DRUG

Irinotecan

Standard of care chemotherapy regimen

DRUG

Topotecan

Standard of care chemotherapy regimen

DRUG

Lurbinectedin

Standard of care chemotherapy regimen

Sponsors & Collaborators

  • Fox Chase Cancer Center

    lead OTHER

Principal Investigators

  • Julia Judd, DO · Fox Chase Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-22
Primary Completion
2028-08-01
Completion
2029-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05800587 on ClinicalTrials.gov